A practical reference on Adsorption: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC, 214 nm | Wavelength affects relative peak areas |
| Identity confirmation | LC-MS/MS | Precursor and fragment ion masses compared |
| Common degradation | Deamidation, oxidation | Amide and methionine residues are main sites |
| Working solution storage | 2-8 °C, short term | Longer holding favours frozen aliquots |
| Adsorption risk | Higher below 1 mg/mL | Glass and plastic surfaces both affected |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
The compression and extension of a bond may be likened to the behaviour of a spring, but real molecules are hardly perfectly elastic in nature. If a bond between atoms is stretched, for instance, there comes a point at which the bond breaks and the molecule dissociates into atoms. Thus real molecules deviate from perfect harmonic motion and their molecular vibrational motion is anharmonic. An empirical expression that fits the energy curve of a diatomic molecule undergoing anharmonic extension and compression to a good approximation was derived by P.M. Morse, and is called the Morse function. Using the Schrödinger equation leads to the selection rule for the system undergoing vibrational changes :
Vitamin D3 24-hydroxylase is an oxidoreductase that uses molecular oxygen in an oxidation reaction which requires adrenal ferredoxin to transfer electrons from nicotinamide adenine dinucleotide phosphate to its cytochrome P450 active site.
Critical fission reactors are the most common type of nuclear reactor. In a critical fission reactor, neutrons produced by fission of fuel atoms are used to induce yet more fissions, to sustain a controllable amount of energy release. Devices that produce engineered but non-self-sustaining fission reactions are subcritical fission reactors. Such devices use radioactive decay or particle accelerators to trigger fissions. Critical fission reactors are built for three primary purposes, which typically involve different engineering trade-offs to take advantage of either the heat or the neutrons produced by the fission chain reaction:
Sources: en.wikipedia.org
Flowers which are particularly suitable for such a treatment are roses, peonies, camellias, marigolds, globe flowers, orchids, dahlias, carnations, phloxes, summer chrysanthemums, hollyhocks, and the like, and other species with many petals or a fairly rigid structure.
=== Political === The company and its founders are major contributors, via the Outback Steakhouse PAC, to the Republican Party, contributing $303,015 and $334,197 for the 2000 and 2004 election cycles, respectively. The PAC remains active, giving $428,000 to federal candidates in the 2017–2018 cycle and raising $464,074 in the 2019–2020 cycle. Since the 2022 cycle its activity has substantially decreased. The PAC gave $93,000 to 37 federal candidates in 2022, and only $12,700 in contributions were recorded from the company in the 2024 cycle. The Outback Steakhouse PAC itself is historically one of the largest donors in the food and beverage sector, second only to the National Restaurant Association, which itself represents 300,000 restaurants.
== Discovery == The N-acetylmuramoyl-L-alanine amidase enzymatic activity was first observed in human and mouse serum in 1981 by Branko Ladešić and coworkers. The enzyme (abbreviated NAMLAA) was then purified from human serum by this and other groups. The sequence of 15 N-terminal amino acids of NAMLAA was identified, but the cDNA for the protein was not cloned and the gene encoding NAMLAA was not known. In 2000, Dan Hultmark and coworkers discovered a family of 12 Peptidoglycan Recognition Protein (PGRP) genes in Drosophila melanogaster and by homology searches of available human and mouse sequences predicted the presence of long forms of human and mouse PGRPs, which they named PGRP-L by analogy to long forms of insect PGRPs. In 2001, Roman Dziarski and coworkers discovered and cloned three human PGRPs, named PGRP-L, PGRP-Iα, and PGRP-Iβ (for long and intermediate size transcripts), and established that human genome codes for a family of 4 PGRPs: PGRP-S (short PGRP) and PGRP-L, PGRP-Iα, and PGRP-Iβ. Subsequently, the Human Genome Organization Gene Nomenclature Committee changed the gene symbols of PGRP-S, PGRP-L, PGRP-Iα, and PGRP-Iβ to PGLYRP1 (peptidoglycan recognition protein 1), PGLYRP2 (peptidoglycan recognition protein 2), PGLYRP3 (peptidoglycan recognition protein 3), and PGLYRP4 (peptidoglycan recognition protein 4), respectively, and this nomenclature is currently also used for other mammalian PGRPs. Sergei Kiselev and coworkers also independently cloned mouse PGLYRP2 (which they named TagL).
== Evolution == There are five groups of TNNI in vertebrates, the extra two known as TNNI4 and TNNI5 (only found in non-amniotes). They are more similar to TNNI1 than to TNNI2 and TNNI3. Likewise, there are four groups of TNNT in vertebrates, with TNNT4 (only found in cartilaginous fishes, ray-finned fishes and lungfish) most closely resembling TNNT2. In most vertebrates and some non-vertebrate chordates, TNNI and TNNT genes tend to occur in pairs next to each other. It is likely that an ancestor to vertebrates had one such pair, which was duplicated into four during the two rounds of whole-genome duplication in early vertebrate evolution, with TNNT5 arising as an additional tandem dupliaction of TNNT4. Most vertebrates express TNNI1 and/or TNNI5 in the heart, whereas adult tetrapods (such as mammals) use TNNI3. Embryonic mammals use TNNI1 in the heart. In humans and teterapods in general, TNNI3 differ from the other TnI genes by having an N-termianl extension; a strikingly similar extension is found in the TNNI5 of cartilaginous, non-teleost ray-finned, and sarcopterygian fishes. Ray finned fishes do not have TNNI3 at all. Substituting TNNI3 for TNNI1 may confer increased tolerance to acidosis. Considering the similarity between TNNI and TNNT, the gene pair may have been the result of an even more ancient tandem duplication event.
Sources: en.wikipedia.org
== External links == Histology image: 77_04 at the University of Oklahoma Health Sciences Center – "Slide 77 skeletal muscle" Anatomy Atlases – Microscopic Anatomy, plate 05.83 – "Smooth Muscle" Diagram at kctcs.edu
The first Este dukes ruled well and the city achieved an economic and cultural peak: Borso's successor Duke Ercole I had the city of Modena rebuilt according to plans designed by Biagio Rossetti, his successors were patrons of artists like Titian and Ludovico Ariosto. In the War of the League of Cambrai from 1508, troops from Modena fought in Papal service against the Republic of Venice. Upon the death of Duke Alfonso II in 1597, the ducal line became extinct. The Este lands were bequeathed to Alfonso's cousin Cesare d'Este; however, the succession was not acknowledged by Pope Clement VIII and Ferrara was finally seized by the Papacy. Cesare was able to retain Modena and Reggio as Imperial fiefs. In the 1628 War of the Mantuan Succession, the dukes of Modena sided with Habsburg Spain and in turn received the town of Correggio from the hands of Emperor Ferdinand II. During the War of the Spanish Succession, Duke Rinaldo was ousted by French troops under Louis Joseph, Duke of Vendôme, he could not return until 1707. In 1711 the small Duchy of Mirandola was absorbed by the Este. His successor Francesco III backed France in the 1740 War of the Austrian Succession and was expelled by Habsburg forces, but his duchy was restored by the 1748 Treaty of Aix-la-Chapelle. In 1796 Modena was again occupied by a French army under Napoleon, who deposed Duke Ercole III and created the Cispadane Republic out of his territory.
== Other uses == Maison du Sport International, an office complex in Lausanne, Switzerland Maritime safety information, emergency signal communication Medical Service Insurance, the Government of Nova Scotia's health insurance Mid-Season Invitational, an annual League of Legends tournament Mindless Self Indulgence, an American rock band Multistakeholder initiative, a governance structure Inshore minesweeper (US Navy hull classification symbol: MSI), See List of mine warfare vessels of the United States Navy
== Composition == Guinness stout is made from water, malted barley, roasted barley, hops, and brewer's yeast. A portion of the barley is roasted to give Guinness its dark colour and characteristic taste. It is pasteurised and filtered. Until the late 1950s, Guinness was still racked into wooden casks. In the late 1950s and early 1960s, Guinness ceased brewing cask-conditioned beers and developed a keg brewing system with aluminium kegs replacing the wooden casks; these were nicknamed "iron lungs". Until 2016 the production of Guinness, as with many beers, involved the use of isinglass made from fish. Isinglass was used as a fining agent for settling out suspended matter in the vat. The isinglass was retained in the floor of the vat but it was possible that minute quantities might be carried over into the beer. Diageo announced in February 2018 that the use of isinglass in draught Guinness was to be discontinued and an alternative clarification agent would be used instead, making the drink acceptable to vegans and vegetarians.
=== Odessa Cubbage === Colonel Odessa Cubbage (voiced by John Patrick Lowrie) is a member of the Resistance against the Combine who speaks in distinct Received Pronunciation. He wears a jacket with emblems on it indicating that he was possibly once a security officer as part of the University of Rochester Security Services. According to Raising the Bar, his model was based on the martial arts instructor for one of the game's developers, and the name was found in a spam filter. Odessa Cubbage leads a small Resistance base and town, dubbed "New Little Odessa", in a coastal region outside City 17. Before arriving at New Little Odessa, the player can see Cubbage speaking with the G-Man by looking through a binocular spotting-scope device. When Gordon Freeman arrives at New Little Odessa en route to Nova Prospekt, Cubbage is briefing members on the use of the rocket launcher against Combine gunships. Cubbage entrusts the rocket launcher to Gordon and never turns up to fight himself, instead staying behind to attempt to contact another Resistance settlement.
Sources: en.wikipedia.org
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.
Peptides can bind to glass and plastic, so a fraction of the material leaves the solution. The effect is proportionally larger in dilute samples and can bias quantitative results.
Reverse-phase high-performance liquid chromatography is the most widely reported approach. Purity figures should always be quoted together with the wavelength, gradient, and integration parameters used.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.